This a retrospective study examining two-year outcomes of patients with pachychoroid neovasculopathy (PNV) treated with a treat and extend (T&E) regimen of intravitreal aflibercept. The mean age was 63.84 ± 7.92 years with nine males (35%) and 17 females (65%). Best corrected visual acuity (BCVA), central macular thickness (CMT), choroidal subfoveal thickness (CST), choroidal thickness (CT) under type 1 choroidal neovascularization (CNV), pigment epithelium detachment (PED) height and presence of subretinal fluid (SRF), intraretinal fluid (IRF) and wet macula were evaluated at baseline and after three, six, 12 and 24 months. BCVA remained stable during the follow-up (p= 0.161). A significant diminution of CMT was found (p= 0.001). Conversely, PED height diminution was not significative (p= 0.260). CST and CT under type 1 CNV improved significantly during the follow-up (p= 0.005 and 0.009, respectively). Patients received an average number of 12.34 ± 6.01 intravitreal injections. The authors conclude that a T&E regimen with intravitreal aflibercept in Caucasian patients with PNV may be effective for improving CMT, CST, CT under type 1 CNV and wet macula, and to stabilise vision, with a personalised regimen of intravitreal injections.
Two-year results of a T&E aflibercept regime in caucasian PNV
Reviewed by Su Young
Two-year results of a treat and extend regimen with aflibercept in caucasian patients with pachychoroid neovasculopathy.
